| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Disofenin targets the hepatobiliary system for diagnostic imaging. As a radiopharmaceutical, it is administered intravenously and is taken up by hepatocytes and excreted into the bile. Its distribution and clearance are used to assess liver function and biliary tract patency. The compound itself does not have a therapeutic target but serves as a carrier for the radioactive isotope technetium-99m.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for Disofenin as a pharmacological agent are not documented in the literature. Its primary application is as a radiopharmaceutical for diagnostic imaging. The compound's utility lies in its ability to be labeled with technetium-99m and its hepatic uptake and biliary excretion properties. It is not characterized for direct biological activities such as enzyme inhibition or receptor modulation.
|
| ln Vivo |
In vivo, Disofenin is used as a radiopharmaceutical for hepatobiliary imaging. Following intravenous administration, the compound is taken up by hepatocytes and excreted into the bile, allowing visualization of the liver, gallbladder, and biliary tract using gamma scintigraphy. It is used to assess liver function, diagnose biliary obstruction, and evaluate gallbladder motility. The compound's diagnostic utility is well established in nuclear medicine.
|
| Enzyme Assay |
In vitro assays for Disofenin are not typically conducted, as it is a radiopharmaceutical used for diagnostic imaging. Its properties are evaluated in vivo through hepatobiliary scintigraphy. The compound's radiochemical purity and stability are assessed using analytical methods such as HPLC and TLC. Its biodistribution and clearance are evaluated in preclinical and clinical studies.
|
| Cell Assay |
Disofenin is not used in cell-based assays as a test compound. Its primary application is as a radiopharmaceutical for diagnostic imaging. The compound's interactions with hepatocytes and biliary excretion are studied in vivo rather than in cell culture. Its use is limited to nuclear medicine applications.
|
| Animal Protocol |
In vivo animal studies with Disofenin are conducted to evaluate its biodistribution, clearance, and imaging properties. The compound is administered intravenously to rodents or other animal models, and its uptake in the liver and excretion into the bile are monitored using gamma scintigraphy. These studies are essential for the development and validation of hepatobiliary imaging agents. All procedures comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Disofenin has a molecular weight of 350.41 g/mol and a molecular formula of C₁₈H₂₆N₂O₅. It is a radiopharmaceutical agent used in hepatobiliary imaging. When labeled with technetium-99m, it is used for diagnostic scintigraphy of the liver and gallbladder. The compound is typically stored under conditions recommended for radiopharmaceuticals.
|
| Toxicity/Toxicokinetics |
Disofenin is a radiopharmaceutical used for diagnostic imaging and is not intended for therapeutic use. Its safety has been evaluated in the context of its use as a diagnostic agent. Adverse effects are rare and may include allergic reactions. The compound is administered under the supervision of qualified medical personnel in nuclear medicine settings. It is not approved for human therapeutic applications outside of diagnostic use.
|
| Additional Infomation |
Disofenin is an amino acid amide.
Disofenin (DISIDA) (CAS#: 65717-97-7) has a molecular formula of C₁₈H₂₆N₂O₅ and a molecular weight of 350.41 g/mol. It is also known as diisopropyl iminodiacetic acid. Disofenin is a radiopharmaceutical agent primarily used in hepatobiliary scintigraphy for diagnostic imaging of the liver and gallbladder. This compound is not a therapeutic drug and is used for diagnostic purposes. |
| Molecular Formula |
C18H26N2O5
|
|---|---|
| Molecular Weight |
350.41
|
| Exact Mass |
350.184
|
| CAS # |
65717-97-7
|
| PubChem CID |
171682
|
| Appearance |
White to off-white solid powder
|
| Density |
1.228 g/cm3
|
| Boiling Point |
567.2ºC at 760 mmHg
|
| Melting Point |
188 - 190°C (lit.)
|
| Flash Point |
296.8ºC
|
| Index of Refraction |
1.575
|
| LogP |
2.416
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
25
|
| Complexity |
446
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C1=C(NC(CN(CC(O)=O)CC(O)=O)=O)C(C(C)C)=CC=C1)C
|
| InChi Key |
UDUSOMRJOPCWHT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H26N2O5/c1-11(2)13-6-5-7-14(12(3)4)18(13)19-15(21)8-20(9-16(22)23)10-17(24)25/h5-7,11-12H,8-10H2,1-4H3,(H,19,21)(H,22,23)(H,24,25)
|
| Chemical Name |
2-[carboxymethyl-[2-[2,6-di(propan-2-yl)anilino]-2-oxoethyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8538 mL | 14.2690 mL | 28.5380 mL | |
| 5 mM | 0.5708 mL | 2.8538 mL | 5.7076 mL | |
| 10 mM | 0.2854 mL | 1.4269 mL | 2.8538 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
